How Has the Transthyretin Amyloidosis Treatment Market Evolved Historically and What is its Current Size?
The transthyretin amyloidosis treatment market has seen considerable growth due to a variety of factors.
• The market for treating transthyretin amyloidosis has seen robust growth in the recent past. The market, which was valued at $5.52 billion in 2024, is projected to reach $5.95 billion in 2025, experiencing a compound annual growth rate (CAGR) of 7.8%.
This historical growth trend has been attributed to factors like higher awareness of the disease, advances in diagnostic technologies, developments and approvals of new drugs, improved patient advocacy and support, and collaboration in research.
What is the Forecasted Market Size and CAGR for the Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for the treatment of transthyretin amyloidosis is projected to experience significant growth in the coming years. By 2029, it is anticipated to be worth $8.04 billion, exhibiting a compound annual growth rate (CAGR) of 7.8%.
This growth during the projected period is owed to an enlarged treatment pipeline, enhanced genetic testing, worldwide initiatives for awareness of rare diseases, personalized medicine methods, and better access to treatment. Notable trends within this forecast period include the emergence of combination therapies, strategic collaborations for drug progression, emphasis on addressing peripheral and cardiac manifestations, execution of patient education programs, and the inclusion of real-world evidence in treatment regulations.
What Key Factors and Trends Are Driving The Growth Transthyretin Amyloidosis Treatment Market?
The augmentation in funds devoted to research and development is anticipated to drive the expansion of the transthyretin amyloidosis treatment market. Such investments encompass financial accommodations for pursuits that serve to enhance scientific comprehension, conceive contemporary technologies, produce groundbreaking products, and enhance existing processes. A boost in funding for research and development facilitates the find and formulation of ground-breaking treatment alternatives for transthyretin amyloidosis. This includes innovative drugs, gene therapies, and precision medicine techniques, providing patients with more successful, focused treatment selections. For instance, Alnylam Pharmaceuticals, a US-based biopharmaceutical firm involved in the development of Vutrisiran, a therapy for ATTR amyloidosis, amplified its research and development investment from $792,156 in 2021 to $883,015 in 2022, signifying a growth of 11.49%. Consequently, the escalation in investment in research and development is set to fuel the transthyretin amyloidosis treatment market's growth. The demographics of the aging population and its subsequent rise are forecasted to stimulate the transthyretin amyloidosis treatment market's growth. Aging population alludes to a demographic change marked by a surge in the median age of a population due to lower fertility rates and increasing life expectancy. Aging significantly contributes to the risk factor for transthyretin amyloidosis (ATTR), and as the population ages, there is a higher prevalence of Transthyretin Amyloidosis cases. This results in an escalating pool of patients necessitating treatment. For instance, the World Health Organization, a Switzerland-based branch of the United Nations handling global public health, stated in October 2022 that every nation globally is witnessing a growth in both the quantity and proportion of older persons in the population. It is projected that by 2030, one in six individuals globally will be 60 years or older. Thus, the growth in the aging population's demographics is propelling the transthyretin amyloidosis treatment market's expansion.
What Are The Market Segments In The Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis treatment market covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM
Pre-Book The Transthyretin Amyloidosis Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Transthyretin Amyloidosis Treatment Industry?
Leading players in the transthyretin amyloidosis treatment marketplace are concentrating their efforts on the creation of novel and unique treatment modalities, such as specialized orphan drugs, to improve patient well-being and broaden available treatment alternatives. Eplontersen is an orphan drug that has been tailored to address the transthyretin amyloidosis condition and often enjoys regulatory incentives to aid its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a biotechnology research firm based in Canada, obtained approval from the Food and Drug Administration (FDA) for a new drug application for Eplontersen. This experimental orphan drug is designed for the treatment of familial transthyretin-mediated amyloid, leading to the advancement of polyneuropathy. Eplontersen is a medicinal compound created to reduce the production of transthyretin (TTR) protein, tackling both hereditary and sporadic types of ATTR amyloidosis (amyloid transthyretin amyloidosis). Eplontersen was bestowed with the orphan drug status by the FDA in 2022.
Who Are the Key Players In The Transthyretin Amyloidosis Treatment Market?
Major companies operating in the transthyretin amyloidosis treatment market report are:
• Pfizer Inc.
• Abbvie Inc.
• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca PLC
• GSK PLC
• Novo Nordisk A/S
• Merck & Co. Inc.
• Astellas Pharma Inc.
• Alexion Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• PTC Therapeutics
• Ionis Pharmaceuticals
• Prothena Corporation PLC
• BridgeBio Pharma Inc.
• Sorrento Therapeutics Inc.
• Intellia Therapeutics
• Akcea Therapeutics Inc.
• Eidos Therapeutics Inc.
• Acrotech Biopharma Inc.
• Spectrum Pharmaceuticals Inc.
• Neurimmune AG
• BELLUS Health Inc.
• Corino Therapeutics Inc.
• Celgene Corp
• SOM Innovation Biotech S.A
What Are The Regional Insights Into The Transthyretin Amyloidosis Treatment Market?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
